Dipak Kumar KUMAR RAJ

Prof. Dipak Kumar KUMAR RAJ

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2004 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
DRDipak Kumar KUMAR RAJ
Dipak Kumar KUMAR RAJ
BDBibhu Ranjan DAS
Bibhu Ranjan DAS
ADA. P. Dash
A. P. Dash
PSPrakash C. Supakar
Prakash C. Supakar
A number of stage-specific antigens have been characterized for vaccine development in Plasmodium falciparum malaria. The polymorphic merozoite surface protein 1 (MSP-1) of Plasmodium falciparum is a major asexual blood stage malaria vaccine candidate antigen. In the present study, we analyzed the impact of hyperendemic malaria transmission, mesoendemic malaria transmission, and multiple infection on allelic diversity. We have used a simple strategy of polymerase chain reaction amplification and slot-blot hybridization to analyze variable regions of block-2, block-4 and blocks 6–10 of the MSP-1 gene. The allelic types of isolates collected from regions of hyperendemic malaria transmission (RHEMT) and mesoendemic malaria transmission (RMEMT) were compared. In RHEMT, 20 of 24 possible gene types were found among 163 isolates and more than one allelic type was found in 82 (50.3%) of the isolates. Thirteen of 24 possible gene types were found among 125 isolates in RMEMT and 27 (21.6%) of them contained more than one allele type. Our results suggest for the first time that the allelic distribution or allelic diversity and chances of finding multi-strain parasites in isolates in an area vary with the rate of transmission. Analyses of isolates containing more than one strain of parasite suggest that allelic types are randomly distributed, no specific type of alleles predominately show multi-strain infection, and neither strain of the parasite affect the process of infection and development of another.

3 August 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
IMIan Michelow
Ian Michelow
SPSangshin Park
Sangshin Park
STShu-Whei Tsai
Shu-Whei Tsai
BRBonnie Rayta
Bonnie Rayta
Charisse Flerida PasajeCharisse Flerida Pasaje
Charisse Flerida Pasaje
JKJonathan D. Kurtis
Jonathan D. Kurtis
We previously identified a Plasmodium falciparum (Pf) protein of unknown function encoded by a single-copy gene, PF3D7_1134300, as a target of antibodies in plasma of Tanzanian children in a whole-proteome differential screen. Here we characterize this protein as a blood-stage antigen that localizes to the surface membranes of both parasitized erythrocytes and merozoites, hence its designation as Pf erythrocyte membrane and merozoite antigen 1 (PfEMMA1). Mouse anti-PfEMMA1 antisera and affinity-purified human anti-PfEMMA1 antibodies inhibited growth of P. falciparum strains by up to 68% in growth inhibition assays. Following challenge with uniformly fatal Plasmodium berghei (Pb) ANKA, up to 40% of mice immunized with recombinant PbEMMA1 self-cured, and median survival of lethally infected mice was up to 2.6-fold longer than controls (21 vs. 8 d, P = 0.005). Furthermore, high levels of naturally acquired human anti-PfEMMA1 antibodies were associated with a 46% decrease in parasitemia over 2.5 yr of follow-up of Tanzanian children. Together, these findings suggest that antibodies to PfEMMA1 mediate protection against malaria.

4 September 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
SPSangshin Park
Sangshin Park
SPSunthorn Pond-Tor
Sunthorn Pond-Tor
FOFredrick Olewe
Fredrick Olewe
CNChristina Nixon
Christina Nixon
RSRonald Stuart
Ronald Stuart
JKJonathan D Kurtis
Jonathan D Kurtis
Background: Current licensed malaria vaccines are modestly protective against severe Plasmodium falciparum malaria but do not contain components which control blood-stage infection. We evaluated the impact of antibodies to 3 blood-stage candidate antigens (P. falciparum glutamic acid-rich protein [PfGARP], P. falciparum schizont egress antigen 1 [PfSEA-1], and P. falciparum glycophorin-binding protein 130 [PfGBP130]) on P. falciparum infection and disease in a longitudinal cohort of children living in a holoendemic region of Western Kenya. Methods: We enrolled and followed up 266 children aged 2–7 years living in Western Kenya. Over the course of a 3-year follow-up period, we actively assessed their health status weekly, collected blood samples monthly to assess P. falciparum infection incidence and intensity and measure immunoglobulin G antibody levels to blood-stage vaccine candidate antigens. Results: Children with high levels of immunoglobulin G antibodies to PfGBP130 or PfGARP, but not PfSEA-1, experienced 3.4- and 1.9-fold lower parasite densities, respectively, than those with low antibody levels (both P < .002). In addition, children with high levels of both anti-PfGBP130 and anti-PfGARP had significantly lower risk of clinical malaria than children with low antibody levels (hazard ratio, 0.58 [95% confidence interval, .85–.40]). Over the 3-year follow-up period, individuals with elevated anti-PfGBP130 and anti-PfGARP antibody levels experienced an average of 4.51 cases of clinical malaria while those with lower levels experienced an average of 7.11 cases (P = .005). Conclusions: Higher antibody levels to PfGBP130 and PfGARP predict significantly lower parasite densities and lower risks of clinical malaria among 2–7-year-old children residing in a holoendemic area of Kenya.

6 May 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
ASAhmad Rushdi Shakri
Ahmad Rushdi Shakri
AMAlok Das Mohapatra
Alok Das Mohapatra
Jhasketan BadhaiJhasketan Badhai
Jhasketan Badhai
AAAditya Anand
Aditya Anand
AVAlvin Varghese
Alvin Varghese
DRDipak Kumar KUMAR RAJ
Dipak Kumar KUMAR RAJ
Background/Objectives: Malaria affects almost half of the world’s population and causes more than 600,000 deaths annually. Young children in malaria-endemic areas have the highest mortality rate because of their immature immune systems. Global efforts to control the disease have had limited success, with two WHO-recommended pre-erythrocytic malaria vaccines showing suboptimal efficacy; no vaccine has yet been approved against the blood stages of the parasite that causes the clinical symptoms of malaria. Therefore, there is an urgent need to identify new vaccine candidates against the parasite’s blood stages to achieve protection against the disease. Methods: Previous studies in our lab identified a few potential vaccine candidates expressed on the surface of malaria-parasite-infected RBCs using sera from disease-resistant children from malaria-endemic regions and a phage-displayed cDNA library generated from P. falciparum. In an innovative approach, we successfully immunized mice using live Plasmodium falciparum-infected red blood cells {Pf-iRBCs (L)}, the membrane fraction of P. falciparum-infected RBCs {Pf-iRBCs (M)}, and live uninfected human red blood cells (hRBCs) in suitable adjuvants. The polyclonal sera produced against Pf-iRBC immunizations were evaluated for specificity and parasite inhibition in vitro and used in a phage display biopanning assay to identify novel antigens on the surface of Pf-iRBCs. Results: Our data indicate that the polyclonal serum produced in BALB/cJ mice, against live Pf-iRBC (L) and their membrane fraction, specifically interacts with surface antigens of parasitic origin on Pf-iRBCs. Additionally, the anti-Pf-iRBC polyclonal serum exhibits significant parasite-killing activity in the in vitro growth inhibition assay (GIA). We have identified both known and novel antigens associated with the Pf-iRBC membrane using phage display cDNA library screening assays. Conclusions: As a proof of concept, our phage display screening identified antigens known to be associated with the Pf-iRBC membrane. Additionally, we identified several unknown Pf-iRBC antigens predicted to be associated with Pf-iRBC membrane (PlasmoDB), suggesting that our approach has the potential to identify novel antigens yet to be evaluated as vaccine candidates against falciparum malaria. In our follow-on studies, we will evaluate the newly identified antigen using an integrated in vitro and in vivo challenge experiment. These studies form the core supporting data for further evaluation of the vaccine potential of novel Pf-iRBC antigens and for follow-on vaccine trials in non-human primates, with an ultimate goal of a malaria vaccine for humans.